| 2026 |
Kumari P, Germon ZP, Jackson ER, Vo T, Dun MD, 'The redox paradox in HGGs: ROS as drivers and destroyers', Trends in Cancer, 12, 420-433 (2026) [C1]
|
|
|
| 2026 |
Thomas B, Persson M, Jackson E, Bartlett F, Germon Z, Rana M, Duchatel R, McEwen H, Findlay I, Douglas A, Kobbe B, Wagener R, Larsen M, Faridi P, Mayall J, Horvat J, Dun M, 'ID #221 Reactivation of fetal extracellular matrix programs drives immune exclusion in diffuse midline glioma', Neuro-Oncology Pediatrics, 2 (2026)
|
|
|
| 2026 |
Kumari P, Germon Z, Jackson E, Dun M, 'ID #819 Targeting reactive oxygen species to modulate the epigenome of diffuse midline glioma', Neuro-Oncology Pediatrics, 2 (2026)
|
|
|
| 2026 |
Dubois O, Persson M, Jackson E, Beitaki T, Duchatel R, Vo T, Douglas A, Savary C, Dun M, 'ID #415 Dordaviprone (ONC201) induces tumour cell states shift in diffuse midline glioma after acute and chronic treatment', Neuro-Oncology Pediatrics, 2 (2026)
|
|
|
| 2026 |
Sanguino YC, Fox S, Rodriguez de la Fuente L, Cassim A, Li S, Kearney P, Jackson E, Duchatel R, Holliday H, Tsoli M, Dun M, Mora FV, 'ID #448 Epigenomic erosion and enhancer dependence in H3.3K27M diffuse midline glioma', Neuro-Oncology Pediatrics, 2 (2026)
|
|
|
| 2026 |
Sanguino YC, Fox S, Cassim A, de la Fuente LR, Li S, Jackson E, Duchatel R, Holliday H, Gopalakrishnan A, Tsoli M, Ziegler D, Ortega DG, Dun M, Mora FV, 'ID #674 Unmasking Epigenomic Vulnerabilities in Diffuse Midline Glioma to Guide Epigenetic Therapy', Neuro-Oncology Pediatrics, 2 (2026)
|
|
|
| 2026 |
Vo T, Savary C, Jackson ER, Douglas AM, Murdoch HJ, Jayaraman R, Bessler N, Persson ML, McEwen H, McLachlan T, Duchatel RJ, Petraello B, Agnihotri S, Anastas J, Baker SJ, Becher OJ, Castel D, Chavez L, Koldobskiy MA, Deogharkar A, Mota M, Dirks PB, Doherty R, de la Nava D, Duncan B, du Chatinier A, Galban S, Marques JG, Hanson CM, Hara T, Herrington C, Ji S, Jones C, Kleinman CL, Krug B, Lin FY, Lu QR, Messinger D, Mody RJ, Mukherji D, Parthasarathy A, Peterson E, Phoenix TN, Pichumani K, Prensner JR, Ramakrishna S, Ramsoomair CK, Sajjakulnukit P, Sarmashghi S, Syed S, Tamplin OJ, Trout M, Freytag S, Valvo VM, Wahl DR, Al-Holou WN, Wechsler-Reya RJ, Koschmann C, Venneti S, Filbin MG, Dun MD, 'Cutting through complexity: Spatial multi-omics in the fight against diffuse intrinsic pontine glioma/diffuse midline glioma', Neuro-Oncology Pediatrics, 2
|
|
|
| 2026 |
Palacios-Alonso D, Hervás-Corpión I, de la Nava D, Nuin S, Beasain I, Fueyo J, Gomez-Manzano C, McLachlan T, Jackson E, Xu J, Dun M, Ausejo-Mauleon I, Casares N, Alonso M, 'ID #1041 Evaluation of the antitumor effect of paxalisib in combination with oncolytic virotherapy for Diffuse Midline Glioma', Neuro-Oncology Pediatrics, 2 (2026)
|
|
|
| 2026 |
Loughnan O, Persson M, Jackson E, Douglas A, Duchatel R, Vo T, Beitaki T, Murdoch H, Lally M, Jayaraman R, Findlay I, Savary C, Dun M, 'ID #898 Dordaviprone (ONC201) reverses T-cell sequestration in diffuse midline glioma models.', Neuro-Oncology Pediatrics, 2 (2026)
|
|
|
| 2026 |
Savary C, Vo T, Jackson E, Persson M, Douglas A, McEwen H, McLachlan T, Kline C, Franson A, Waszak S, Nazarian J, Koschmann C, Mueller S, Dun M, 'ID #666 Deciphering cellular sates associated with response to dordaviprone (ONC201) in diffuse midline glioma patients from the PNOC022 clinical trial', Neuro-Oncology Pediatrics, 2 (2026)
|
|
|
| 2026 |
Rana M, Thomas B, Jackson E, Bartlett F, Germon Z, Vo T, Dun M, 'ID #870 Immune-competent organoid fusion models to study extra cellular matrix dynamics in atypical teratoid rhabdoid tumour', Neuro-Oncology Pediatrics, 2 (2026)
|
|
|
| 2025 |
Duchatel R, Jackson E, Findlay I, Vo T, Savary C, Beitaki T, Douglas A, Dun M, 'DMG-29. Targeting oncogenic plasticity in DIPG: A combined paxalisib and avapritinib approach to enhance survival outcomes', Neuro-Oncology Pediatrics, 1 (2025)
|
|
|
| 2025 |
Jackson E, Riley M, Duchatel R, McEwen H, Persson M, Findlay I, Beitaki T, Lally M, Douglas A, Kline C, Nazarian J, Koschmann C, Mueller S, Dun M, 'DMG-09. Targeting the PI3K/AKT/mTOR genetic dependency in combination with ONC201 for the treatment of diffuse midline glioma', Neuro-Oncology Pediatrics, 1 (2025)
|
|
|
| 2025 |
Savary C, Persson ML, Jackson ER, Vo T, Duchatel RJ, Douglas AM, de la Fuente LR, Colino-Sanguino Y, Mora FV, Dun MD, 'DMG-08. Single-Cell Analysis of ONC201 and Paxalisib Resistance Mechanisms in Diffuse Intrinsic Pontine Glioma', Neuro-Oncology Pediatrics, 1 (2025)
|
|
|
| 2025 |
Jackson E, Duchatel R, Vo T, Savary C, Germon Z, Riley M, McEwen H, Persson M, Findlay I, Beitaki T, Lally M, Douglas A, Rogers MKN, Fonkem E, Franson A, Kline C, Nazarian J, Koschmann C, Mueller S, Dun M, 'EXTH-89. Precision Targeting of PI3K/mTOR in Diffuse Midline Glioma: GCT007 as a Novel Brain-Penetrant PIK3CA Inhibitor', Neuro-Oncology, 27, v359-v360 (2025)
|
|
|
| 2025 |
Dun M, Jackson E, Findlay I, Vo T, Savary C, Douglas A, Germon Z, Mannan A, Persson M, Thomas B, Jayaraman R, Newell-Rogers K, Fonkem E, Wu C-C, Ameratunga M, Duchatel R, 'EXTH-83. Exploiting Cell-of-Origin Vulnerabilities to Guide Multimodal Strategies in Diffuse Midline Glioma', Neuro-Oncology, 27, v358-v358 (2025)
|
|
|
| 2025 |
Persson M, Savary C, Jackson E, Duchatel R, Bramberger L, de la Nava D, Thomas B, McEwen H, Beitaki T, Findlay I, Douglas A, Larsen M, Faridi P, Holst J, Mayall J, Hondermarck H, Horvat J, Nixon B, Cartaxo R, Nazarian J, Hulleman E, Mueller S, Vitanza N, Koschmann C, Alonso M, Carvalheiro T, van der Lugt J, Dun M, 'DMG-30. ONC201 induces immune-tumor surveillance and alters the tumor immune microenvironment of diffuse midline glioma models', Neuro-Oncology Pediatrics, 1 (2025)
|
|
|
| 2025 |
Duchatel RJ, Savary C, Germon ZP, Riley M, Ziegler DS, Mueller S, Jackson ER, Dun MD, 'Beyond base camp: PI3K/mTOR inhibition for the treatment of pediatric high-grade gliomas', Neuro Oncology, 27, 2789-2803 (2025) [C1]
|
|
|
| 2025 |
Findlay I, Staudt D, Duchatel R, Jackson E, Kearny P, Persson M, McEwen H, Delevaux K, Smith N, Vitanza N, Cain J, Hansen M, Alvaro F, Waszak S, Dun M, 'DMG-16. Integrative proteogenomic analysis for improved therapeutic decision-making in diffuse midline glioma', Neuro-Oncology Pediatrics, 1 (2025)
|
|
|
| 2024 |
Jackson ER, Persson ML, Fish CJ, Findlay IJ, Mueller S, Nazarian J, Hulleman E, van der Lugt J, Duchatel RJ, Dun MD, 'A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered', NEURO-ONCOLOGY, 26, S136-S154 (2024) [C1]
|
|
Open Research Newcastle |
| 2024 |
Arms LM, Duchatel RJ, Jackson ER, Sobrinho PG, Dun MD, Hua S, 'Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma', JOURNAL OF CONTROLLED RELEASE, 370, 835-865 (2024) [C1]
|
|
Open Research Newcastle |
| 2024 |
Duchatel RJ, Jackson ER, Parackal SG, Kiltschewskij D, Findlay IJ, Mannan A, Staudt DE, Thomas BC, Germon ZP, Laternser S, Kearney PS, Jamaluddin MFB, Douglas AM, Beitaki T, McEwen HP, Persson ML, Hocke EA, Jain V, Aksu M, Manning EE, Murray HC, Verrills NM, Sun CX, Daniel P, Vilain RE, Skerrett-Byrne DA, Nixon B, Hua S, de Bock CE, Colino-Sanguino Y, Valdes-Mora F, Tsoli M, Ziegler DS, Cairns MJ, Raabe EH, Vitanza NA, Hulleman E, Phoenix TN, Koschmann C, Alvaro F, Dayas C, Tinkle CL, Wheeler H, Whittle JR, Eisenstat DD, Firestein R, Mueller S, Valvi S, Hansford JR, Ashley DM, Gregory SG, Kilburn LB, Nazarian J, Cain JE, Dun MD, 'PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma', JOURNAL OF CLINICAL INVESTIGATION, 134 (2024) [C1]
|
|
Open Research Newcastle |
| 2023 |
Noll A, Myers C, Biery MC, Meechan M, Tahiri S, Rajendran A, Berens ME, Paine D, Byron S, Zhang J, Winter C, Pakiam F, Leary SES, Cole BL, Jackson ER, Dun MD, Foster JB, Evans MK, Pattwell SS, Olsona JM, Vitanza NA, 'Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma', NEOPLASIA, 43 (2023) [C1]
|
|
Open Research Newcastle |
| 2023 |
Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Le Grand M, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, Andre N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD, 'ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma', CANCER RESEARCH, 83, 2421-2437 (2023) [C1]
|
|
Open Research Newcastle |
| 2023 |
Staudt DE, Murray HC, Skerrett-Byrne DA, Smith ND, Jamaluddin MFB, Kahl RGS, Duchatel RJ, Germon ZP, McLachlan T, Jackson ER, Findlay IJ, Kearney PS, Mannan A, McEwen HP, Douglas AM, Nixon B, Verrills NM, Dun MD, 'Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection (vol 19, 48, 2022)', CLINICAL PROTEOMICS, 20 (2023)
|
|
|
| 2023 |
Germon ZP, Sillar JR, Mannan A, Duchatel RJ, Staudt D, Murray HC, Findlay IJ, Jackson ER, McEwen HP, Douglas AM, McLachlan T, Schjenken JE, Skerrett-Byrne DA, Huang H, Melo-Braga MN, Plank MW, Alvaro F, Chamberlain J, De Iuliis G, Aitken RJ, Nixon B, Wei AH, Enjeti AK, Huang Y, Lock RB, Larsen MR, Lee H, Vaghjiani V, Cain JE, de Bock CE, Verrills NM, Dun MD, 'Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies', SCIENCE SIGNALING, 16 (2023) [C1]
|
|
Open Research Newcastle |
| 2022 |
Findlay IJ, De Iuliis GN, Duchatel RJ, Jackson ER, Vitanza NA, Cain JE, Waszak SM, Dun MD, 'Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies', ONCOGENE, 41, 461-475 (2022) [C1]
Diffuse midline glioma (DMG) is a deadly pediatric and adolescent central nervous system (CNS) tumor localized along the midline structures of the brain atop the spinal... [more]
Diffuse midline glioma (DMG) is a deadly pediatric and adolescent central nervous system (CNS) tumor localized along the midline structures of the brain atop the spinal cord. With a median overall survival (OS) of just 9¿11-months, DMG is characterized by global hypomethylation of histone H3 at lysine 27 (H3K27me3), driven by recurring somatic mutations in H3 genes including, HIST1H3B/C (H3.1K27M) or H3F3A (H3.3K27M), or through overexpression of EZHIP in patients harboring wildtype H3. The recent World Health Organization's 5th Classification of CNS Tumors now designates DMG as, 'H3 K27-altered', suggesting that global H3K27me3 hypomethylation is a ubiquitous feature of DMG and drives devastating transcriptional programs for which there are no treatments. H3-alterations co-segregate with various other somatic driver mutations, highlighting the high-level of intertumoral heterogeneity of DMG. Furthermore, DMG is also characterized by very high-level intratumoral diversity with tumors harboring multiple subclones within each primary tumor. Each subclone contains their own combinations of driver and passenger lesions that continually evolve, making precision-based medicine challenging to successful execute. Whilst the intertumoral heterogeneity of DMG has been extensively investigated, this is yet to translate to an increase in patient survival. Conversely, our understanding of the non-genomic factors that drive the rapid growth and fatal nature of DMG, including endogenous and exogenous microenvironmental influences, neurological cues, and the posttranscriptional and posttranslational architecture of DMG remains enigmatic or at best, immature. However, these factors are likely to play a significant role in the complex biological sequelae that drives the disease. Here we summarize the heterogeneity of DMG and emphasize how analysis of the posttranslational architecture may improve treatment paradigms. We describe factors that contribute to treatment response and disease progression, as well as highlight the potential for pharmaco-proteogenomics (i.e., the integration of genomics, proteomics and pharmacology) in the management of this uniformly fatal cancer.
|
|
Open Research Newcastle |
| 2022 |
Staudt DE, Murray HC, Skerrett-Byrne DA, Smith ND, Jamaluddin MFB, Kahl RGS, Duchatel RJ, Germon ZP, McLachlan T, Jackson ER, Findlay IJ, Kearney PS, Mannan A, McEwen HP, Douglas AM, Nixon B, Verrills NM, Dun MD, 'Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection', CLINICAL PROTEOMICS, 19 (2022) [C1]
|
|
Open Research Newcastle |
| 2022 |
McLachlan T, Matthews WC, Jackson ER, Staudt DE, Douglas AM, Findlay IJ, Persson ML, Duchatel RJ, Mannan A, Germon ZP, Dun MD, 'B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers', MOLECULAR CANCER RESEARCH, 20, 1711-1723 (2022) [C1]
B-cell lymphoma 6 (BCL6) is a protooncogene in adult and pediatric cancers, first identified in diffuse large B-cell lymphoma (DLBCL) where it acts as a repressor of th... [more]
B-cell lymphoma 6 (BCL6) is a protooncogene in adult and pediatric cancers, first identified in diffuse large B-cell lymphoma (DLBCL) where it acts as a repressor of the tumor suppressor TP53, conferring survival, protection, and maintenance of lymphoma cells. BCL6 expression in normal B cells is fundamental in the regulation of humoral immunity, via initiation and maintenance of the germinal centers (GC). Its role in B cells during the production of high affinity immunoglobins (that recognize and bind specific antigens) is believed to underpin its function as an oncogene. BCL6 is known to drive the self-renewal capacity of leukemia-initiating cells (LIC), with high BCL6 expression in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and glioblastoma (GBM) associated with disease progression and treatment resistance. The mechanisms underpinning BCL6-driven therapy resistance are yet to be uncovered; however, high activity is considered to confer poor prognosis in the clinical setting. BCL6's key binding partner, BCL6 corepressor (BCOR), is frequently mutated in pediatric cancers and appears to act in concert with BCL6. Using publicly available data, here we show that BCL6 is ubiquitously overexpressed in pediatric brain tumors, inversely to BCOR, highlighting the potential for targeting BCL6 in these often lethal and untreatable cancers. In this review, we summarize what is known of BCL6 (role, effect, mechanisms) in pediatric cancers, highlighting the two sides of BCL6 function, humoral immunity, and tumorigenesis, as well as to review BCL6 inhibitors and highlight areas of opportunity to improve the outcomes of patients with pediatric cancer.
|
|
Open Research Newcastle |
| 2022 |
Sanguino YC, de la Fuente LR, Kisswani D, Kearney P, Jackson E, Duchatel R, Holliday H, Jabado N, Tsoli M, Ziegler D, Dun M, Mora FV, 'DIPG-37. Exploring the role of the epigenetic factor H2A.Z acetylation in DIPG', Neuro-Oncology, 24, i26-i27 (2022)
|
|
|
| 2022 |
Dun MD, Jackson ER, Duchatel RJ, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara S, Le Grand M, Kearney PS, Douglas AM, Findlay IJ, Staudt D, Germon ZP, Skerrett-Byrne DA, Nixon B, Smith ND, Hulleman E, Day B, McCowage GB, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, Vitanza NA, Nazarian J, Koschmann C, Cain J, Mueller S, 'DIPG-07. Preclinical and case study results underpinning the phase II clinical trial testing the combination of ONC201 and paxalisib for the treatment of patients with diffuse midline glioma (NCT05009992)', Neuro-Oncology, 24, i18-i19 (2022)
|
|
|
| 2022 |
Persson M, Jackson E, Duchatel R, Bramberger L, McEwen H, Kearney P, Findlay I, Douglas A, Kobbe B, Wagener R, Larsen M, Faridi P, Holst J, Mayall J, Gedye C, Hondermarck H, Horvat J, Nixon B, Cartaxo R, Koschmann C, Valdes-Mora F, Ortega DG, Nazarian J, Alonso MM, Hulleman E, Van der Lugt J, Vitanza N, Mueller S, Dun M, 'TMIC-06. ANTAGONISM OF DRD2 USING ONC201 INCREASED EXPRESSION OF ANTIGEN PRESENTATION PATHWAY PROTEINS IN DIFFUSE MIDLINE GLIOMA, RECRUITING TUMOR INFILTRATING LYMPHOCYTES IN VIVO', Neuro-Oncology, 24, vii272-vii272 (2022)
|
|
|
| 2022 |
Findlay I, Staudt D, Kearney P, McEwen H, Duchatel R, Jackson E, Beitaki T, Smith N, Vitanza N, Firestein R, Cain J, Mueller S, Pasquier E, Koschmann C, Hulleman E, Nazarian J, Hansen M, Alvaro F, Davis M, Waszak S, Dun M, 'CSIG-10. PHARMACO-PHOSPHO-PROTEO-GENOMICS OF PEDIATRIC HIGH-GRADE GLIOMAS – A PILOT STUDY', Neuro-Oncology, 24, vii40-vii41 (2022)
|
|
|
| 2022 |
Jackson E, Duchatel R, Persson M, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara S, Le Grand M, Kearney P, Douglas A, Findlay I, Staudt D, Germon Z, Skerrett-Byrne D, Nixon B, Smith N, Hulleman E, Day B, McCowage G, Alvaro F, Waszak S, Larsen M, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, Vitanza N, Nazarian J, Koschmann C, Cain J, Mueller S, Dun M, 'EXTH-12. PRECLINICAL AND CASE STUDY EXAMINATION OF THE COMBINATION OF THE CLPP AGONIST ONC201 WITH THE PI3K/AKT INHIBITOR PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA', Neuro-Oncology, 24, vii211-vii211 (2022)
|
|
|
| 2021 |
Duchatel RJ, Mannan A, Woldu AS, Hawtrey T, Hindley PA, Douglas AM, Jackson ER, Findlay IJ, Germon ZP, Staudt D, Keamey PS, Smith ND, Hindley KE, Cain JE, Andre N, La Madrid AM, Nixon B, De Luliis GN, Nazarian J, Irish K, Alvaro F, Eisenstat DD, Beck A, Vitanza NA, Mueller S, Morris JC, Dun MD, 'Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma', NEURO-ONCOLOGY ADVANCES, 3 [C1]
|
|
Open Research Newcastle |
| 2020 |
Jackson ER, Duchatel RJ, Mannan A, Hulleman E, Carcaboso AM, Monje M, McCowage GB, Alvaro F, Dun MD, 'AKT SIGNALING DRIVES RESISTANCE TO ONC201 IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)', NEURO-ONCOLOGY, 22, 293-293 (2020)
|
|
|
| 2020 |
Duchatel RJ, Mannan A, Jackson ER, Staudt D, Skerrett-Byrne DA, Jamaluddin MFB, Woldu AS, Douglas A, Hulleman E, Carcaboso AM, Monje M, Alvaro F, Tsoli M, Ziegler DS, Dun MD, 'DIPG-29. PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE (PI3K) INHIBITION DRIVES PROTEIN KINASE C ACTIVATION (PKC) IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)', Neuro-oncology, 22, iii292-iii293 (2020)
|
|
|
